首页> 外文期刊>Cancer causes and control: CCC >Hormone Replacement Therapy, Reproductive History, and Colorectal Adenomas: Data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States).
【24h】

Hormone Replacement Therapy, Reproductive History, and Colorectal Adenomas: Data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States).

机译:激素替代疗法,生殖史和结直肠腺瘤:来自前列腺癌,肺癌,结直肠癌和卵巢癌(PLCO)癌症筛查试验的数据(美国)。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: Findings from some epidemiologic studies of colorectal cancer and adenoma suggest that the protective effect of post-menopausal hormone replacement therapy (HRT) may differ across categories of age and body mass index (BMI). We conducted an analysis of women participating in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to investigate the relationship between HRT use and prevalent adenoma, both overall and across different population subgroups. METHODS: Women aged 55-74 were randomized to screening by flexible sigmoidoscopy at ten PLCO screening centers between September 1993 and September 2001. We identified 1468 women with at least one left-sided adenoma and 19,203 without adenoma or colorectal cancer. Information about HRT and reproductive factors was obtained from a self-administered questionnaire. RESULTS: Compared to never use of HRT, current use was associated with a decreased prevalence of left-sided adenoma (odds ratio (OR) 0.85; 95% confidence interval (CI) 0.75-0.97). We found no evidence of dose-response with increasing duration of use for current or former users. The association with current HRT use was stronger among women aged 65+ (OR 0.69; 95% CI 0.56-0.84), with a BMI<30 (OR 0.82; 95% CI 0.71-0.95) and who regularly use aspirin or ibuprofen (OR 0.77; 95% CI 0.65-0.91). Other reproductive factors were not significantly associated with adenoma prevalence. CONCLUSIONS: Our findings suggest that current HRT use may protect against colorectal adenoma, and that this protective effect is short-lived following cessation of use.
机译:目的:从一些大肠癌和腺瘤的流行病学研究发现,绝经后激素替代疗法(HRT)的保护作用可能在年龄和体重指数(BMI)类别之间有所不同。我们对参与前列腺癌,肺癌,结肠直肠癌和卵巢癌(PLCO)癌症筛查试验的妇女进行了分析,以调查HRT使用与普遍的腺瘤之间的关系,无论是总体还是不同人群。方法:在1993年9月至2001年9月之间,在10个PLCO筛查中心对55-74岁的女性进行了柔性乙状结肠镜检查,其中包括1468例患有至少一个左侧腺瘤的妇女和19203例无腺瘤或结直肠癌的妇女。有关HRT和生殖因子的信息是从自我管理的问卷中获得的。结果:与从未使用HRT相比,当前使用与左侧腺瘤的患病率降低相关(优势比(OR)为0.85; 95%置信区间(CI)为0.75-0.97)。我们发现目前或以前的使用者使用持续时间都没有剂量反应的证据。在65岁以上(OR 0.69; 95%CI 0.56-0.84),BMI <30(OR 0.82; 95%CI 0.71-0.95)且经常使用阿司匹林或布洛芬(OR)的女性中,与当前HRT使用的相关性更强0.77; 95%CI 0.65-0.91)。其他生殖因素与腺瘤患病率无显着相关。结论:我们的发现表明,目前使用HRT可以预防结直肠腺瘤,并且这种保护作用在停止使用后是短暂的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号